Table 2 Relationship between the clinical symptoms and adenomyosis location.
From: Effects of localization of uterine adenomyosis on clinical features and pregnancy outcome
Group A (N = 32) | Group B (N = 70) | Group C (N = 56) | P value | |
|---|---|---|---|---|
Length of menstrual cycle(day) | 27.75 (23–35) | 28.56 (15–60) | 29.24 (23–43) | 0.26 |
Length of period(day) | 5.91 (3–10) | 6.12 (3–15) | 6.09 (2–15) | 0.74 |
Duration of dysmenorrhea(month) | 60 (0–180) | 54 (0–288) | 48 (0–360) | 0.45 |
Pain symptoms, n(%) | 21 (65.6%) | 54 (77.1%) | 45 (80.4%) | 0.29 |
Dysmenorrhea (VAS) | 3 (0–10) | 6 (0–10) | 6.5 (0–10) | 0.06 |
Dyspareunia, n(%) | 2 (6.3%) | 8 (11.4%) | 8 (14.3%) | 0.52 |
Rectal tenesmus, n(%) | 3 (9.4%) | 19 (27.1%) | 13 (23.2%) | 0.12 |
Intestinal symptoms, n(%) | 2 (6.3%) | 14 (20.0%) | 5 (8.9%) | 0.07 |
CPP, n(%) | 3 (9.4%) | 9 (12.9%) | 10 (17.9%) | 0.50 |
HMB, n(%) | 4 (12.5%)a,b | 20 (28.6%)b | 7 (12.5%)a | 0.04 |
